Take-home message: Though anti-vascular endothelial growth factor therapy for diabetic macular edema showed impressive results in trials, clinicians have reported less success on their own.
St. Louis, MO—Anti-vascular endothelial growth factor (VEGF) treatments for diabetic macular edema (DME) have not worked as well in clinical practice as in clinical trials, according to one clinician.
“Treatment was less effective than in the registration trials, most likely due to the infrequency of the injections,” said Kevin J. Blinder, MD, partner, The Retina Institute, and professor of clinical ophthalmology and visual sciences, Washington University in Saint Louis, MO.
To examine this phenomenon, Dr. Blinder and his colleagues, in a trial sponsored by Allergan, reviewed the records of 156 patients who had received at least three anti-VEGF injections for DME at 10 sites.
The patients’ mean age was 63.4 years. More than 80% had type II diabetes, and more than 40% had a history of focal laser photocoagulation treatments.